There are studies [40, 41] indicating that several kinds of PPARγ agonists, such as thiazolidinediones, are expected to combine with chemotherapeutic agents or other target medications to work as a second-line treatment regimen, in the hope of improving the prognosis of patients with advanced colorectal cancer. The gene discussed is PPARG; the disease is colorectal cancer.